Trial Profile
Outcomes of sequential treatment with Crizotinib followed by Alectinib in patients with ALK+ Non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology